Ecofi Investissements SA Has $9.13 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Ecofi Investissements SA grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,150 shares of the medical research company’s stock after buying an additional 850 shares during the quarter. IQVIA accounts for 5.6% of Ecofi Investissements SA’s investment portfolio, making the stock its 5th biggest position. Ecofi Investissements SA’s holdings in IQVIA were worth $9,131,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at about $33,000. GKV Capital Management Co. Inc. bought a new position in IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA in the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc grew its stake in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Barclays reaffirmed an “equal weight” rating and issued a $170.00 price target (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. Stephens initiated coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Finally, Citigroup cut their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.50.

IQVIA Stock Performance

NYSE:IQV opened at $143.66 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $25.33 billion, a P/E ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The firm has a 50 day moving average of $176.42 and a 200-day moving average of $196.86. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.